Adults and children above 30 kg: 200mg BD. Children 16 to <20 kg: 100 mg BID. 20 to <25 kg: 125 mg BID. Children 25 to <30 kg: 150 mg BID. It is taken after meals.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
It is a new generation Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI).
Significant reduction of absorption (of up to 50%) when taken in an empty stomach.
Allergy to the drug or any excipient of the formulation.
Mild rash; nausea; diarrhea; peripheral neuropathy; allergic reactions such as Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis; and autoimmune disorders that may include Graves‘ disease, polymyositis, and Guillain-Barre syndrome.
Drug interactions: It is a substrate of the cytochrome P450 enzyme system as well as being an inducer of CYP3A4 hence leading to the decrease in plasma concentrations of a number of drugs. Thus, it should not be co-administered with carbamazepine, phenobarbital, phenytoin, rifampin, rifabutin, St. John‘s wort, fosamprenavir/ritonavir and a full-dose of ritonavir.
Treatment-experienced patients lack virologic response to at least two ARV regimens, with at least one member be-longing to NRTI, NNRTI and protease inhibitor.
Etravirine has a high genetic barrier to the emergence of viral resistance, and it maintains its antiviral activity in the presence of common NNRTI mutations[a]
In a phase III clinical trial of Etravirine on treatment-experienced patients, 62% of patients in the Etravirine group and 44% in the placebo group achieved confirmed viral load below 50 copies per mL at week 24